胸腺肽联合抗结核药物治疗复治涂阳肺结核的临床分析  

Clinical analysis of thymosin combined with anti-tuberculosis drugs in the treatment of smear-positive pulmonary tuberculosis

作　　者：田娇 TIAN Jiao(Jinzhou Infectious Disease Hospital,Jinzhou 121000,China)

机构地区：[1]锦州市传染病医院,121000

出　　处：《中国现代药物应用》2020年第19期128-129,共2页Chinese Journal of Modern Drug Application

摘　　要：目的研究胸腺肽联合抗结核药物治疗复治涂阳肺结核患者的临床疗效。方法72例复治涂阳肺结核患者,依治疗方法不同分为观察组与对照组,各36例。观察组应用胸腺肽联合抗结核药物治疗,对照组应用抗结核药物治疗。比较两组患者痰菌转阴率、治疗效果及不良反应发生率。结果观察组患者痰菌转阴率、治疗总有效率、不良反应发生率分别为94.44%、88.89%、11.11%,均优于对照组的75.00%、69.44%、30.56%,差异均具有统计学意义(P<0.05)。结论复治涂阳肺结核患者采用胸腺肽联合抗结核药物治疗,可以有效提升患者治疗的整体痰菌转阴率和总体治疗效果,同时降低患者的不良反应发生率,整体治疗过程中具有较高的安全性,值得推广。Objective To study the clinical efficacy of thymosin combined with anti-tuberculosis drugs in the treatment of smear-positive pulmonary tuberculosis.Methods A total of 72 patients with smear-positive pulmonary tuberculosis were divided into observation group and control group according to different treatment methods,with 36 cases in each group.The observation group was treated with thymosin combined with anti-tuberculosis drugs,and the control group was treated with anti-tuberculosis drugs.The sputum negative-conversion rate,therapeutic effect and occurrence of adverse reactions were compared between the two groups.Results The sputum negative-conversion rate,total effective rate and occurrence of adverse reactions of the observation group were 94.44%,88.89%and 11.11%,which were better than 75.00%,69.44%and 30.56%of the control group,and the difference was statistically significant(P<0.05).Conclusion Application of thymosin combined with anti-tuberculosis drugs to treat patients with smearpositive pulmonary tuberculosis can effectively improve the overall sputum conversion rate and the overall therapeutic effect of the patients,and reduce the incidence of adverse reactions of the patient.It has high safety in the overall treatment process,and is worth promoting.

关 键 词：胸腺肽 抗结核药物 复治涂阳型肺结核 

分 类 号：R521[医药卫生—内科学]